室管膜瘤治療市場：按藥物類型、疾病類型、分銷渠道、地區 - 規模、份額、展望、機會分析，2022-2030 年

室管膜瘤是一種罕見的腦腫瘤，稱為神經膠質瘤。 它起源於大腦和脊髓中的室管膜細胞。 室管膜瘤可發生於兒童和成人。 一種柔軟的灰色或紅色腫瘤，可能包含囊腫或礦物質鈣化。 室管膜瘤的症狀取決於腫瘤是在大腦中還是在脊髓中。 室管膜瘤有四種主要類型：亞獨立性室管膜瘤、粘液乳頭狀室管膜瘤、間變性室管膜瘤和經典室管膜瘤。 室管膜瘤的症狀與腫瘤的位置和大小有關。 在嬰兒中，首發症狀之一是頭部變大。 隨著腫瘤的增大，可出現煩躁、失眠、嘔吐等症狀。 噁心、嘔吐和頭痛是年齡較大的兒童和成人最常見的症狀。

市場動態

全球室管膜瘤治療市場的主要參與者正專注於增加室管膜瘤的研究和開發，預計這將在預測期內推動市場增長。 例如，2022 年 4 月，兒科腦腫瘤聯合會啟動了一項針對複發性髓母細胞瘤和室管膜瘤兒科患者的基於靜脈注射 ombutamab 的放射免疫療法的 2 期試驗。 該試驗計劃於 2030 年 7 月 30 日結束。 此外，增加室管膜瘤的研究經費預計將在預測期內推動全球室管膜瘤藥物市場的增長。 例如，2021 年 11 月，由耶魯大學公共衛生學院的研究人員領導的一組科學家著手研究主要影響年輕人的低級神經膠質瘤（生長緩慢但惡性的腦腫瘤）的分子進化。它有獲得了 1300 萬美元的資助。

本研究的主要特點

• 本報告對全球室管膜瘤治療市場進行了深入分析，包括以 2021 年為基準年的預測期（2022-2030 年）的市場規模（百萬美元）和復合年增長率 (CAGR%).
• 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
• 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
• 我們根據公司概況、產品組合、主要亮點、財務業績和戰略等參數對全球室管膜瘤治療市場的主要參與者進行了概況分析。
• 本研究涵蓋的主要公司包括 Fera Pharmaceuticals、Pfizer、Novartis AG、Merck KGaA、Baxter、Cipla Limited、Zydus Cadila、Lupin Pharmaceuticals, Inc.、UCB, Inc.、APOTEX INC 和 Moleculin Biotech., Inc. .
• 這份報告中的見解將使企業營銷人員和高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 《全球室管膜瘤治療市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球室管膜瘤治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按藥物類型
  • 按疾病類型劃分的市場概況
  • 市場概況：按銷售渠道
  • 市場概況：按地區
• 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 商機
• 影響分析
• 監管場景
• 市場趨勢
• 主要發展狀況
• 流行病學
• 害蟲分析
• 合作夥伴關係和收購
• 搬運工分析
• 管道分析

第 4 章室管膜瘤藥物的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 經濟影響
• 對供需的影響
• COVID-19 影響評估

第 5 章全球室管膜瘤藥物市場，按藥物類型，2017-2030

• 腎上腺皮質類固醇
• 抗驚厥藥
• 其他

第 6 章全球室管膜瘤藥物市場：按疾病類型分類，2017-2030

• 室管膜下瘤
• 黏液乳頭狀室管膜瘤
• 間變性室管膜瘤
• 經典室管膜瘤

第 7 章室管膜瘤藥物全球市場：分銷渠道，2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 8 章全球室管膜瘤藥物市場：地區，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 法國
• 意大利
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 澳大利亞
• 韓國
• 東盟
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第9章競爭格局

• 熱圖分析
• 市場份額分析
  • Fera Pharmaceuticals.
  • Pfizer
  • Novartis AG
  • Merck KGaA,
  • Baxter
  • Cipla Limited
  • Zydus Cadila
  • Lupin Pharmaceuticals, Inc.
  • UCB, Inc.
  • APOTEX INC
  • Moleculin Biotech, Inc.,

第 10 章

• 調查方法介紹
• 關於出版商

Ependymoma is a rare type of brain tumour called a glioma. It starts from ependymal cells in the brain or spinal cord. Ependymomas can develop in children and adults. They are soft, grayish, or red tumors which may contain cysts or mineral calcifications. Symptoms of ependymomas depend on whether the tumor is in the brain or the spinal cord. These tumors are divided into four major types, subependymoma, myxopapillary ependymoma, anaplastic ependymoma and classic ependymomas. Symptoms of an ependymoma are related to the location and size of the tumor. In infants, increased head size may be one of the first symptoms. Irritability, sleeplessness, and vomiting may develop as the tumor grows. In older children and adults, nausea, vomiting, and headache are the most common symptoms

Market Dynamics

Key players operating in the global ependymoma drug market are focusing on increasing research and development for ependymoma which is expected to drive the market growth during the forecast period. For instance, in April 2022, Pediatric Brain Tumor Consortium initiated Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma. The study is estimated to be completed in July 30, 2030. Moreover, increasing research funding for ependymoma is expected to propel growth of the global ependymoma drug market over the forecast period. For instance, in November 2021, a team of scientists led by researchers at the Yale School of Public Health had received a US $13 million grant to investigate the molecular evolution of lower grade gliomas, slow growing but malignant brain tumors that primarily affect young adults.

Key features of the study:

• This report provides an in-depth analysis of the global ependymoma drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ependymoma drug market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ependymoma drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ependymoma drug market

Detailed Segmentation:

• Global Ependymoma Drug Market, By Drug Type:
  • Corticosteroids
  • Antiseizure Agents
  • Others
• Global Ependymoma Drug Market, By Disease Type :
  • Subependymoma
  • Myxopapillary Ependymoma
  • Anaplastic Ependymoma
  • Classic Ependymomas
• Global Ependymoma Drug Market, By Distribution Channel :
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Global Ependymoma Drug Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Fera Pharmaceuticals *
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer .
  • Novartis AG
  • Merck KGaA
  • Baxter
  • Cipla Limited
  • Zydus Cadila
  • Lupin Pharmaceuticals, Inc.,
  • UCB, Inc.,
  • APOTEX INC,
  • Moleculin Biotech, Inc

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channels
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunity
• Impact Analysis
• Regulatory Scenario
• Market Trends
• Key Developments
• Epidemiology
• PEST Analysis
• Collaboration and Acquisition
• Porters Analysis
• Pipeline Analysis

4. Global Ependymoma Drug Market- Impact of Coronavirus (COVID-19) Pandemic

• Economic Impact
• Impact on Demand and Supply
• COVID-19 Impact Assessments

5. Global Ependymoma Drug Market, By Drug Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Antiseizure Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Others
  • Introduction dna
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Ependymoma Drug Market, By Disease Type, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Subependymoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Myxopapillary Ependymoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Anaplastic Ependymoma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Classic Ependymomas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

7. Global Ependymoma Drug Market, By Distribution Channel, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Retail Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Online Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Ependymoma Drug Market, By Region, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
  • Fera Pharmaceuticals.*
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Pfizer
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Merck KGaA,
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Baxter
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Cipla Limited
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Zydus Cadila
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Lupin Pharmaceuticals, Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • UCB, Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • APOTEX INC
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Moleculin Biotech, Inc.,
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies

10. Section

• Research Methodology
• About us